Sprint Bioscience AB Share Price

Equities

SPRINT

SE0006343745

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 12:54:35 30/04/2024 pm IST 5-day change 1st Jan Change
1.33 SEK +1.84% Intraday chart for Sprint Bioscience AB -0.45% -23.34%

Financials

Sales 2024 * 118M 10.76M 898M Sales 2025 * 199M 18.15M 1.52B Capitalization 92.86M 8.47M 707M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 0.04 x
Net cash position 2024 * 88.2M 8.05M 671M Net cash position 2025 * - 0 0 EV / Sales 2025 * 0.47 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 28
Yield 2024 *
-
Yield 2025 *
-
Free-Float 47.2%
More Fundamentals * Assessed data
Dynamic Chart
Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sprint Bioscience Licenses the Vada Program to Day One Biopharmaceuticals CI
Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Vivesto Names Sprint Bioscience Boss as New CEO; Shares Down 6% MT
Sprint Bioscience Reports Novel AMLarget Proteins in Ongoing Collaboration CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Sprint Bioscience Launches NIMA at BIO International CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021 CI
More news
1 day+1.84%
1 week-0.45%
Current month+29.13%
1 month+29.13%
3 months+26.67%
6 months-28.88%
Current year-23.34%
More quotes
1 week
1.20
Extreme 1.196
1.39
1 month
0.97
Extreme 0.974
1.59
Current year
0.76
Extreme 0.756
1.86
1 year
0.45
Extreme 0.451
3.28
3 years
0.45
Extreme 0.4505
9.79
5 years
0.45
Extreme 0.4505
18.80
10 years
0.45
Extreme 0.4505
76.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 40 01/23/01
Founder 53 01/09/01
Director of Finance/CFO 51 01/11/01
Members of the board TitleAgeSince
Director/Board Member 68 01/20/01
Chairman 56 01/21/01
Director/Board Member 48 01/19/01
More insiders
Date Price Change Volume
30/24/30 1.33 +1.84% 17,205
29/24/29 1.306 +1.24% 157,957
26/24/26 1.29 -4.16% 178,498
25/24/25 1.346 -1.03% 96,321
24/24/24 1.36 +4.78% 46,579

Delayed Quote Nasdaq Stockholm, April 30, 2024 at 12:54 pm IST

More quotes
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. SPRINT Stock